Novavax推迟向美国申请紧急使用疫苗 股价急挫
Novavax(NVAX.US)再次推迟提高新冠疫苗生产的时间表,并表示直到第三季都不会寻求美国、英国及欧洲的疫苗使用授权,公司原先预计可能最早在5月获得美国监管机构的批准。
Novavax首季亏损为2.23亿美元,收入为4.47亿美元,公司隔夜股价下跌8.81%,在盘後再急挫12.9%。
Novavax预计在第四季之前不会达到每月1.5亿铲的生产目标,较先前预期的第三季度要迟,目前大约可供应3,000万至4,000万剂疫苗,而工厂亦每周都在增加产量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.